

## COMPILED REFERENCES

- Aakeroy C.B., Fasulo M.E and Desper J. (2007). Cocrystal or salt: does it really matter? *molecular pharmaceutics*, 2(3), 317-322.
- Aakeroy, C.B. and Salmon D.J. (2005). Building co-crystal with molecular sense and supramolecular sensibility. *Cryst. Eng. Comm.*, 439-448.
- A. Rahim S., Fatinah A.R., Engku N.E.M. Nasir and Noor A. Ramli (2015). Carbamazepine co-crystal screening with dicarboxylic acids co-crystal formers. *International Scholarly and scientific research & innovation*, 5, 414-417.
- A. Rahim S., Robert B.H., Ahmad Y.S., and Kevin J.R., (2013). A comparative assessment of the influence of the different crystallization screening methodologies on the solid forms of carbamazepine co-crystal. *Cryst Eng Comm*, 15, 3862-3873
- Bertilson L., and Thomson T. (1986). Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. *Pharmacokinetics*, 11, 177-198.
- Blagden N., Matas M.D., Gavan P.T. and York P. (2007). Crystal growing of active pharmaceutical ingredients to improve solubility and dissolution rates. *Advance drug delivery*, 59, 617-630.
- Bond A. B. (2007). *Cryst Eng Comm*, 9, 833-834.
- Brahmankar D.M. and Jaiswal S.B. (2005). *Biopharmaceutics and Pharmacokinetics* (2 ed.). VallabhPrakashan.
- Byrn S.R., Pfeiffer R.R and Stowell J.G. (1999). *Solid-state chemistry of drugs*. IN: West Lafayette.
- Cabrerra N. and Vermilea D.A. (1958). *Growth Perfection of Crystals* (Vol. 393). London: Chapman and Hall.
- Child S. and Rodriguez-Hornedo N. (2008). Screening strategies based on solubility and solution composition generated pharmaceutically acceptable cocrystals of carbamazepine. *Crystengcomm*, 10(5), 856-864.

- Child S. L. and Hardcastle H.I. (2007). *Cryst. Growth. Des.*, 7, 1291-1304.
- Florence A.J., Johnston A., Price S.L., Nowell H., Kennedy A.R., Shankland N. (2006).  
An automated parallel crystallization search for predicted crystal structures and packing motifs of carbamazepine. *J. Pharm. Sci.*, 95, 1918–1930.
- Gagniere E., Mangin D., Puel F., Rivoire A., Monnier O., Garcia E. and Klein J. P. (2009).  
Formation of co-crystal: kinetic and thermodynamic aspects. *Growth*, 2689-2695.
- Geankoplis C. J. (2014). *Transport processes and separation process principles (Includes unit operations)* (4 ed.). England: Pearson.
- Gillon A., Feeder N., Davey R. and Storey R. (2003). Hydration in molecular crystals - a cambridge structural database analysis. *Crystal growth and design*, 3(5), 663-673.
- Grzesiak A.L., Lang M., Kim K., Matzger A.J. (2003). Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. *J. Pharm. Sci.*, 96, 2686–2702.
- Hickey M. B., Peterson M.L., Scoppettuolo L.A., Morrisette S. L., Vetter A., Guzman H., Julius F. Remenar J.F., Zhang Z., Tawa M. D., Haley S., Zaworotko M.J. and Almarsson O. (2007). Performance comparison of a co-crystal of carbamazepine with marketed product. *European Journal of Pharmaceutics and Biopharmaceutics*, 67, 112-119.
- Jayasankar A., Somwangthanaroj A., Shao Z. J., and Rodriguez H. (2006). *N. Pharmaceutical Research*, 23, 2381-2392.
- Jones W., Motherwell W.D. and Trask A.V. (2006). *MRS Bull*, 341, 875-879.
- Kobayashi Y., Ito S., Itai S., Yamamoto K. (2000). Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. *Int. J. Pharm*, 193, 137–146.
- McCrone W.C. (1965). *Physics and Chemistry* (2 ed.). New York: Interscience.
- Meyer M. C., Straughn A.B., Jarvi E.J., Wood G.C., Pelsor F.R. and Shah V.P. (1992). The bioinequivalence of carbamazepine tablets with a history of clinical failures. *Pharm. Res.*, 9, 1612-1616.

- Miroshnyk I., M. S. (2009). Pharmaceutical co-crystals-an opportunity for drug product enhancement. *Expert Opin. Drug Deliv.*, 6(4), 333-41.
- Morissette S. L., Almarssin O., Peterson M. L., Remenar. J. F., Read M. J., Lemmo A. V., Ellis S., Cima M. J. and Gardner C. R. (2003). high-throughput crystallization:polymorphs, salts, co-crystals and solvates of pharmaceutical solids. *Advance Drug Delivery*, 56, 275-300.
- Motherwell W.D.S., Ammon H.L, Dunitz J.D., Dzyabchenko A., Erk P., Gavezzotti A., Hofmann D.W.M., Leusen, F.J.J., Lommerse J.P.M., Mooij W.T.M., Price S.L., Scheraga H., Schweizer B., Schmidt M.U., van Eikck B.P. Verwer P. and Williams D.E. (2002). Crystal structure prediction of small organic molecules: a second blind test. *Acta Crystallographica*, B(58), 647-661.
- Mundhe A.V., Fuloria N.M. and Biyani K.R. (2013). Cocrystalization:An alternative approach for solid modification. *Journa of drug delivery and therapeutics*, 3(4), 166-172.
- Nangia A., and Bhogala, B.R. (2008). *New J. Chem*, 32, 800-807.
- Padrela,L.,Rodriques,M.A.,Velaga,S.P.,Fernandes, A.C.,Matos,H.A., and Azevedo, E.G. (2010). Screening for pharmaceutical cocrystals using the supercritical fluid enhance atomization process. *The Journal of Supercritical Fluids*. 53,156-164.
- Porter W. W., Elie S. C. and Matzger A. J. (2008). Polymorphism in carbamazepine cocrystals. *Cryst Growth Des.*, 8, 14-16.
- Qiao N. (2014). *Investigation of Carbamazepin-Nootinamide cocrystal solubility and dissolution by a UV imaging system*. Laicester: Faculty of Health and Life Sciences.
- Rager T. and Hilfike R. (2010). Cocrystal formation from solvent mixture. *Crystal growth & design*, 10, 3237-3241.
- Ramle N. A., Abd Rahim S., El-Hadad O. and Anuar N. (2015). Solubility of crabamazepine-succinic co-crystal in ethanolic solvent system. *Advance mateerials research*, 1113, 434-439.

- Rodriguez S. B., Price C.P., Jayasankar A., Matzger A.J. and Rodriguez H. N. (2004). General principals of pharmaceutical solid polymorphism: Asupramolecular perspective. *Adv. Drug delivery rev*, 56, 241-274.
- Schultheiss N. and Newman A. (2009). Pharmaceutical cocrystal and their physicochemical properties. *Cryst. Growth Des*, 9(6), 2950-2967.
- Sehic S., Betz., Hadziidedic S., El-Arini., and Leuenberger H. (2010). Investigation of intrinsic dissolution behavior of different carbamazepine samples. *International Journal of Pharmaceutics*, 386, 77-90.
- Sevukarajan M., Thanuja R., Sodanapalli R., and Nair R. (2011). Synthesis and characterization of a pharmaceutical co-crystal (Aceclofenac:Nicotinamide). *Journal of Pharmaceutical Science and Research*, 3, 1288-1293.
- Shan N. and Michael J. Zaworotko. (2008). The role of cocrystal in pharmaceutical science. *Drug discovery today*, 13, 440-446.
- Sheikh A.Y., Abd Rahim S., Hammond R.M. and Roberts K.J. (2009). Scalable Solution cocrystallization: case of carbamazepine-nicotinamide I. *CrystEngComm*, 501-509.
- Stahly, G. P. (2007). *Cryst. Growth Des*, 7, 1007-1026.
- Thakuria R., Delori A., Jones W., Maya P. Lipert, Roy L. and Hornedo N.R. (2012). Pharmaceutical cocrystal and poorly soluble drugs. *International Journal of Pharmaceutics*, 101-125.
- Vippagunta S.R., Britain H.G and Grant D.T.W. (2001). Crystalline solids. *Adv. Drug Deliv. Rev.*, 48.
- Zakiriah A. N. (2013). *Solid Phase Transformation and Stability of Carbamazepine-Saccharin Co-crystal*. Malaysia: Universiti Malaysia Pahang.
- Zawotko M. J., Vishwesh P., McMahon J., and Bis J. A. (2006). *J. Pharm. Sci.*, 95, 499-516.